Nicola Maggi
 | The topic of this article may not meet Wikitia's general notability guideline. |
Nicola Maggi | |
|---|---|
| Add a Photo | |
| Born | September 7, 1933 Altamura, Italy |
| Citizenship | Italian |
| Occupation | Pharmaceutical chemist |
Nicola Maggi (born 7 September 1933 in Altamura, Italy) is an Italian pharmaceutical chemist known for his role in the discovery and development of rifampicin, a major antibiotic used in the treatment of tuberculosis and other bacterial infections. Maggi was the first author of the 1966 scientific paper that first reported rifampicin, "Rifampicin: a new orally active rifamycin."[1]
Maggi is also listed as the first inventor on the U.S. patent covering rifampicin and related rifamycin derivatives.
Rifampicin later became a cornerstone drug in modern tuberculosis therapy and remains included on the World Health Organization’s List of Essential Medicines.[2]
Research career
Maggi carried out his research at the pharmaceutical company Lepetit S.p.A. in Milan, which in the post-war period became an important European center for antibiotic discovery. Within Lepetit’s rifamycin research program, Maggi and colleagues worked on the isolation, chemical modification, and pharmacological evaluation of rifamycin derivatives, with the aim of improving their oral bioavailability and therapeutic efficacy.[3]
His research focused in particular on the semisynthesis of natural antibiotics and on the study of structure–activity relationships in rifamycin compounds, contributing to the development of rifamycins from experimental compounds into clinically usable drugs.[4]
Contribution to the discovery of rifampicin
Maggi is the first author of the scientific publication that first described rifampicin. In 1966, Maggi and colleagues reported the compound in the article "Rifampicin: a new orally active rifamycin," published in the journal Chemotherapy.[1]
The paper described rifampicin as a novel rifamycin derivative with strong antibacterial activity and effective oral bioavailability, properties that distinguished it from earlier rifamycin antibiotics and enabled its clinical use.
Historical accounts of rifamycin research identify this publication as the first scientific report describing rifampicin.[5][6][7]
Maggi is also listed as the first inventor on the U.S. patent covering rifampicin and related rifamycin derivatives, reflecting his central role in the chemical development of the compound.
Rifampicin was introduced into clinical use in the late 1960s and rapidly became one of the most important antibiotics used in tuberculosis treatment.
Scientific impact
The discovery of rifampicin had a major impact on antimicrobial therapy and tuberculosis control. Rifamycins were shown to inhibit bacterial RNA polymerase, a mechanism of action that represented a new class of antibacterial agents targeting transcription.[8]
Rifampicin soon became a key component of short-course chemotherapy regimens for pulmonary tuberculosis, which significantly improved treatment outcomes and reduced treatment duration.[9]
Subsequent reviews of tuberculosis drug development and pharmacology have described rifampicin as a transformative advance in tuberculosis therapy and one of the most important antibiotics introduced in the second half of the twentieth century.[10][5][6]
Research on rifamycin antibiotics continues to build on the discovery of rifampicin and its mechanism of action, including investigations into new rifamycin derivatives for the treatment of mycobacterial infections.[7]
Academic career
Maggi served as Associate Professor at the University of Bari from 1971 to 2003, where he taught pharmaceutical technology and related subjects in the Faculty of Pharmacy.
Selected publication
- Maggi, N.; Pasqualucci, C. R.; Ballotta, R.; Sensi, P. (1966). "Rifampicin: a new orally active rifamycin". Chemotherapy. 11 (5): 285–292. doi:10.1159/000220462. PMID 5958716.
References
- ↑ 1.0 1.1 Maggi, N.; Pasqualucci, C. R.; Ballotta, R.; Sensi, P. (1966). "Rifampicin: a new orally active rifamycin". Chemotherapy. 11 (5): 285–292. doi:10.1159/000220462. PMID 5958716.
- ↑ "WHO Model List of Essential Medicines – 23rd List, 2023". World Health Organization. 2023. Retrieved 12 March 2026.
- ↑ Sensi, P. (1983). "History of the development of rifampin". Reviews of Infectious Diseases. 5 (Suppl 3): S402–S406.
- ↑ Hartmann, G.; Honikel, K. (1983). "The rifamycins". Antibiotics. Springer.
- ↑ 5.0 5.1 Murray, J. F. (2015). "Treatment of tuberculosis: a historical perspective". Annals of the American Thoracic Society.
- ↑ 6.0 6.1 van Ingen, J.; Aarnoutse, R. (2011). "Why do we use 600 mg rifampicin in tuberculosis treatment?". Clinical Infectious Diseases.
- ↑ 7.0 7.1 Ganapathy, U. S. (2019). "Repositioning rifamycins for Mycobacterium abscessus lung disease". Frontiers in Microbiology.
- ↑ Wehrli, W. (1971). "Actions of the rifamycins". Bacteriological Reviews.
- ↑ Fox, W.; Mitchison, D. A. (1975). "Short-course chemotherapy for pulmonary tuberculosis". American Review of Respiratory Disease.
- ↑ Mitchison, D. A. (2004). "The search for new sterilizing anti-tuberculosis drugs". Frontiers in Bioscience.
External links
This article "Nicola Maggi" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.